CT041

About CARsgen Therapeutics

CARsgen Therapeutics is a clinical-stage biopharma with a mission to develop and commercialize innovative cell therapies for cancer, aiming to make cancer curable. The company has established itself as a notable player in the challenging field of solid tumor CAR-T therapy, with its lead asset CT041 (targeting Claudin18.2) achieving key regulatory designations in both China and the U.S. Its strategy leverages a fully integrated platform spanning discovery to manufacturing, with a dual geographic footprint in Houston, USA, and Shanghai, China, to drive global development.

Therapeutic Areas